TAMBOTATUG PELITECAN
UNII 66NNR5T69Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Tambotatug Pelitecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 66NNR5T69Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2925042-80-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

66NNR5T69Q

CAS Registry Number

2925042-80-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TAMBOTATUG PELITECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188794

National Cancer Institute reference terminology for clinical and research data.

INN ID

13657

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-13

Identifier assigned by the United States Adopted Names Council.

Substance Type

Tambotatug Pelitecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tambotatug Pelitecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tambotatug Pelitecan

Common Names & Synonyms

B386,

Immunoglobulin G1, anti-(human B7 homolog protein B7H3) (human monoclonal YL201 γ1-chain), complex with human monoclonal YL201 κ-chain, dimer, octakis(thioether) with N-[6-(2-mercapto-5-pyrimidinyl)-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]glycinamide

TAMBOTATUG PELITECAN [USAN]

YL 201 [WHO-DD]

immunoglobulin G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7-related protein 2, B7RP2, B7RP-2, B7 homolog 3, B7 homologue 3)], Homo sapiens monoclonal antibody; conjugated on an average of eight cysteinyl residues to pelitecan groups, comprising a linker and a camptothecin derivative (a topoisomerase I inhibitor); H-gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-23*01 (96.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120(217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-215')-disulfide with L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (91.7%) -IGKJ4*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'), V101 (192')) (109'-215')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; substituted at the sulfur atoms of the L -cysteinyl residues 223, 229, 232, 215', 223'', 229'', 232'' and 215''' with 5-[(11S,14S)-11-[4-(dipropylamino)butyl]-1-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl]-7,10,13,16-tetraoxo-14-(propan-2-yl)-4-oxa-6,9,12,15-tetraazahenicos-20-yn-21-yl]pyrimidin-2-yl (pelitecan) groups (tambotatug pelitecan)

tambotatug pelitecan [INN]